The global launch brings image-based morphology intelligence into routine hematology workflows through AI × CBM technology.

Ozelle has officially launched O-Cyte 1, its newest automated hematology analyzer, at ADLM 2026 in Anaheim, California. Built on AI × CBM | Complete Blood Morphology, O-Cyte 1 marks an important step in Ozelle’s vision for the 4th Generation of Hematology Analysis, bringing morphology intelligence, productivity, and operational simplicity together in one compact hematology system.

Modern hematology systems already provide fast, reliable, and highly automated blood cell analysis. As clinical workloads continue to grow, however, laboratories are seeking new ways to incorporate morphology information into routine workflows with greater consistency, visibility, and operational efficiency.

Bringing Image-Based Morphology into Routine Hematology Workflows

O-Cyte 1 is designed for this next stage of hematology analysis. Rather than replacing laboratory expertise, the system adds an image-based morphology layer to automated hematology workflows. Through AI × CBM, cell images are transformed into structured morphology insight, helping laboratories access visible cellular evidence alongside routine hematology results. This approach supports more consistent morphology review while keeping image-based information within the everyday testing workflow.

Scalable Throughput with Simplified Daily Operation

O-Cyte 1 supports up to 60 tests per hour as a standalone unit and up to 360 tests per hour with cascaded expansion, allowing laboratories to expand testing capacity as workloads increase. Its compact design, consumable-contained fluidics, modular architecture, and service-ready design are intended to reduce routine maintenance requirements and support flexible deployment across laboratories, hospitals, health screening centers, and regional diagnostic networks.

An Expanding Clinical Hematology Portfolio

Alongside O-Cyte 1, Ozelle also showcased its expanding clinical hematology portfolio at ADLM 2026. The portfolio includes integrated multi-test diagnostic systems combining hematology, immunoassay, and biochemistry capabilities, as well as compact 7-Diff hematology analyzers with cell imaging and simplified maintenance.

Together, these solutions are designed to support different testing environments—from primary care and decentralized diagnostics to hospital laboratories and regional diagnostic networks.

The introduction of O-Cyte 1 also reflects a broader evolution in Ozelle’s approach to diagnostics: from standalone instruments toward integrated systems engineered for real-world clinical environments. By combining advanced imaging, AI-powered analysis, automation, and maintenance-efficient design, Ozelle aims to make morphology intelligence more accessible, consistent, and practical across diverse clinical settings.

Following its global debut at ADLM 2026, Ozelle will continue working with laboratories, healthcare organizations, and strategic partners worldwide to expand access to AI-powered hematology solutions.

Learn more about O-Cyte 1 or schedule a product briefing with the Ozelle team:https://forms.gle/HWkFmcpzPW2WTM7x9